https://www.selleckchem.com/pr....oducts/carfilzomib-p
Mean improvement from baseline was 6.53 points for T-CBT and -0.27 points for TAU (p less then 0.0001); gains persisted over 6-month follow-up (p less then 0.0001). Improvements were moderated by a reduction in negative thoughts in the T-CBT group only, reflecting treatment target engagement. CONCLUSIONS T-CBT may be an effective depression intervention that addresses a significant unmet PD treatment need and bypasses access barriers to multidisciplinary, evidence-based care. CLINICALTRIALSGOV IDENTIFIER NCT02505737. CLASSIFI
Like
Comment
Share
